In-vitro / Ex Vivo Models and Studies
LIDE complements its in vivo expertise with a diverse suite of in vitro assays, providing scalable, mechanistic, and cost-effective platforms to support oncology drug discovery. From traditional 2D cell lines to advanced patient-derived 3D organoids and immune co-culture systems, our in vitro solutions help bridge the gap between bench research and translational relevance.
| Technology | Purpose | Why LIDE |
|---|---|---|
| Commercial Cell Lines | Widely used, well-characterized tumor cell models for drug screening | Access to hundreds of solid tumor and hematologic cancer lines, including luciferase-tagged and resistant variants |
| Conditionally Reprogrammed (CR) Cells | Retains genetic alterations and drug resistance phenotypes | Hundreds of CRC cultures matched to PDX models; supports seamless in-vitro to in-vivo testing |
| 3D Spheroids & Organoids | More physiologic tumor architecture and drug response compared to 2D cultures | Established from PDX, CRC, or patient tissue; validated correlation with in vivo efficacy; compatible with high-throughput drug screening |
| Co-Culture Assays | Evaluate tumor–immune cell interactions in vitro | Tumor + PBMC, T-cell, NK-cell, or macrophage systems; supports checkpoint inhibitor, bispecific, ADC, and oncolytic virus studies |
| Ex Vivo Tumor Assay | Direct short-term culture of fresh patient tissue for rapid testing | Maintains original tumor microenvironment and immune components; ideal for mechanistic IO studies |